Cartilage Restoration denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cartilage restoration are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Blue Cross Blue Shield Denies Cartilage Restoration as Experimental

Blue Cross Blue Shield plans frequently classify certain cartilage restoration techniques — particularly newer cell-based or biologic approaches — as "experimental, investigational, or unproven" (EIU). BCBS plans maintain technology-assessment policies that evaluate whether procedures have sufficient published evidence to meet their "clinical effectiveness" standard. When the specific technique used (e.g., a particular autologous cell therapy, scaffold-based approach, or newer graft material) has not been affirmatively included in BCBS's coverage policy, it may be denied as experimental even if the FDA has cleared or approved the product.

## Why This Denial Is Appealable

The experimental label is challengeable when peer-reviewed literature, professional society guidelines, and FDA clearance or approval collectively support that the procedure is an accepted standard of care for the specific patient population and indication. Many cartilage restoration techniques that BCBS policies initially classified as experimental have subsequently been reclassified as they accumulated evidence. An appeal that marshals the current evidence base — without overstating it — can be persuasive.

## Federal Appeal Framework

• Internal appeal: File within the Explanation of Benefits deadline. Lead with FDA clearance/approval documentation and cite the applicable professional society position statement or guideline.
• Independent Medical Review for EIU denials: Under ACA §2719, experimental/investigational denials are specifically eligible for external review by a qualified IRO. This is a critical right — use it.
• Expedited review: Available when delay poses serious health risk; important for time-sensitive joint deterioration cases.
• ERISA §503: Full-and-fair review applies to employer plans; external-review window is approximately four months from denial.

## Documentation to Gather

1. FDA clearance or approval documentation — 510(k) clearance letter, PMA approval, or biologics license for the specific product used; highlight the exact cleared/approved indication. 2. Clinical evidence summary — a bibliography and brief summary of peer-reviewed studies supporting use of this technique for your patient's diagnosis; the treating surgeon or a consulting specialist can prepare this. 3. Professional society position — citation to the applicable orthopedic or sports-medicine society guideline or coverage statement supporting the procedure. 4. Patient-specific clinical necessity — surgeon's letter explaining why this technique was selected for this patient's specific lesion characteristics and why it is not investigational in this context. 5. Diagnosis documentation — imaging and arthroscopic findings confirming lesion type, location, and size.

## Criteria-Mapping Structure

Obtain BCBS's current technology-assessment or coverage policy for the specific cartilage restoration technique at issue. Left column of your appeal table: each criterion BCBS uses to define "not experimental" (e.g., FDA status, peer-reviewed evidence, guideline endorsement); right column: the specific document — FDA letter, study citation, or guideline page — that satisfies each criterion. Address BCBS's own evidence standard on its own terms.